Alexandre White-Brown

Alexandre White-Brown

Auto-generated profile, based on publicly available information

Alexandre White-Brown

Department of Medical Genetics, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Genetics in Medicine
Verified
Journal Article
Open access
GEGrace U. Ediae
Grace U. Ediae
AWAlexandre White-Brown
Alexandre White-Brown
CCCaitlin Chisholm
Caitlin Chisholm
ITIvan Terekhov
Ivan Terekhov
JSJon Seymour
Jon Seymour
KBKym M. Boycott
Kym M. Boycott
Undiagnosed rare genetic diseases (RGD) can go unrecognized by health care providers, delaying appropriate genetic testing. This proof-of-concept study aimed to address this barrier through the development of a rule-based search algorithm called "ThinkRare." The algorithm used structured electronic medical record data and clinical criteria to identify patients who may have a complex undiagnosed RGD, are eligible for clinical exome sequencing, and are not yet referred to genetics (true positives). Iterative testing on gold standard and test data sets (input) informed algorithm design and optimization. Medical record reviews were conducted to verify whether the algorithm identified patients (output) were true positives or false positives, and these outcomes informed algorithm modifications. Physicians of identified patients were notified with the option to refer to genetics. The search algorithm was applied retrospectively to 262,296 patients (test data set), excluding 99.9% of patients and identifying 30 patients eligible for exome sequencing. The algorithm's estimated recall (sensitivity) was 60% and precision (positive predictive value) was 15%. This process resulted in the diagnosis of 50% of patients (4/8) referred and evaluated in genetics. The search algorithm effectively identified patients retrospectively with an RGD and prospective deployment will ultimately help physicians "think rare."

30 August 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
AWAlexandre M. White‐Brown
Alexandre M. White‐Brown
MRMarilyn Richard
Marilyn Richard
AMAnne‐Maude Morency
Anne‐Maude Morency
CMChelsea Maedler‐Kron
Chelsea Maedler‐Kron
IBIsabelle De Bie
Isabelle De Bie
Nonimmune foetal hydrops is a prenatal condition associated with significant perinatal mortality. It has so far been associated with over 200 chromosomal and monogenic conditions, most frequently chromosomal aneuploidies and RASopathies. Thorough clinical phenotyping and genetic evaluation are essential to determine the underlying etiology of this clinical entity and guide obstetrical and postnatal management. In this report, we describe the prenatal presentation and postnatal outcome of a pregnancy with Lethal Congenital Glycogen Storage Disease of the Heart, a rare autosomal dominant non lysosomal cardiac glycogenosis caused by a novel de novo likely pathogenic variant in the Protein Kinase AMP‐Activated Non‐Catalytic Subunit Gamma 2 (PRKAG2) gene, [NM_016203.3:c.1150A > G, p.(Arg384Gly)]. To this day, only six other molecularly confirmed prenatal presentations of this condition have been reported. This clinical report adds to the knowledge on the prenatal features, clinical evolution, molecular diagnosis and pathological findings of this disorder and underlines the clinical utility of comprehensive molecular testing in the investigation of nonimmune foetal hydrops and fetal cardiomyopathy.

14 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JPJulianne Postma
Julianne Postma
SHSadegheh Haghshenas
Sadegheh Haghshenas
TBTeija M. I. Bily
Teija M. I. Bily
MIMajdina Isovic
Majdina Isovic
AWAlexandre White-Brown
Alexandre White-Brown
TBTugce B. Balci
Tugce B. Balci
Background: Recurrent constellations of embryonic malformations (RCEMs) comprise multiple malformation conditions with largely unexplained etiologies and no established molecular biomarkers. A shared DNA methylation episignature was recently identified in VACTERL association and oculoauriculovertebral spectrum (OAVS). We sought to validate this episignature in an independent, deeply phenotyped cohort and evaluate its detection across related RCEMs. Methods: Genome-wide DNA methylation profiling was performed on peripheral blood from 38 participants with clinically diagnosed RCEMs, including VACTERL (n=21), partial VACTERL (n=3), OAVS (n=3), and other RCEM-related conditions (n=11). Results: The Episign V5 RCEM episignature demonstrated robust sensitivity for VACTERL (18/21, 85.7% positive), while the remaining three participants showed intermediate positivity. Of three participants with partial VACTERL, one with tracheoesophageal fistula demonstrated intermediate positivity, whereas the other two were negative. Episignature positivity was also identified in oculoauriculofrontonasal dysplasia (1/1, robust) and rhomboencephalosynapsis (1/2, robust) but was limited in OAVS (1/3, intermediate) and absent in frontonasal dysplasia (0/4). Conclusions: Independent validation establishes the Episign V5 RCEM episignature as a reproducible molecular biomarker for VACTERL, a condition that remains a diagnosis of exclusion. Variable detection across related malformation conditions suggests etiologic heterogeneity, whereas overlap among selected phenotypes supports epigenomic convergence across the RCEM spectrum.

23 September 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
AWAlexandre White‐Brown
Alexandre White‐Brown
AMAren Marshall
Aren Marshall
XWXueqi Wang
Xueqi Wang
MTMinh Tran
Minh Tran
TKTara Keays
Tara Keays
DDDavid Dyment
David Dyment